Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800
Indian stock market analysts are optimistic, anticipating the Nifty to continue its upward trend. They suggest buying on dips around the 24,000-24,150 mark, with potential upside targets reaching 24,800. Several stocks, including Container Corporation of India, IndusInd Bank, Biocon, HDFC Asset Management Company, Shriram Finance, and Piramal Pharma, are highlighted as strong buy recommendations with specific price targets and stop-losses.
Elara Securities turns bullish on banks, power, IT after market correction
Bino Pathiparampil, Head of Research, Elara Securities (India), says Indian markets are nearing a medium-term bottom after a prolonged correction and is turning constructive on banks, power, select new-age companies, IT and real estate. While pharma remains a defensive bet, he expects margin pressure to limit near-term outperformance. He also believes IT stocks are gradually pricing in AI-led headwinds, making it a good time to start accumulating quality names.
HealthQuad looking at deeper opportunities in new age healthcare with its Fund III
The early growth investor sees a wider and deeper opportunity across new age healthcare models, as demand and the pipeline of entrepreneurs building stronger, lasting businesses continues to grow
Cipla wants new-age medicines to contribute 10% of revenue in five years
Cipla is expanding its innovation ambitions while building manufacturing capacity in the US, as the drugmaker looks to diversify revenue streams and strengthen supply-chain resilience amid increasing regulatory and localisation pressures in global pharmaceutical markets.
A new-age thirst for beverages is emerging as a key force in India's consumer goods market
Beverage industry in India: Indian companies are seeing strong growth in drinks like coffee, ready-to-drink options, and protein beverages. Younger consumers are driving this trend, seeking convenience and health. Companies are expanding their offerings to meet this demand. This shift presents significant opportunities for future expansion in the Indian beverage market.
Sunil Singhania’s Abakkus Portfolio: 6 stocks rally up to 75% in CY26; 5 new buys added in Q4
Sunil Singhania’s Abakkus Asset Manager portfolio rose 6% to Rs 2,742 crore in March 2026 quarter, with mixed CY26 performance showing strong gains in Avalon Technologies and Suven Life Sciences amid several notable stock declines.
Sensex Today | Stock Market LIVE Updates: GIFY Nifty hints at gap-down; Ashok Leyland in focus
Sensex Today | Stock Market LIVE Updates: Brent continues to remain below $100 a barrel and the bulls would take that with both hands. For levels, 24,000 continues to act as a barrier for the index, while a close above 23,800 will be crucial to head into the new month on a positive note.
Nifty could hit 27,000 once geopolitical tensions ease: Bajaj Finserv AMC CIO
Bajaj Finserv AMC CIO Nimesh Chandan projects 15% earnings growth for Nifty in FY28, with EPS rising to the ₹1,420–1,440 range, making valuations look attractive. He backs metals, construction, and cement as long-term plays on a global supply chain shift, holds gold and silver in the multi-asset portfolio, and flags El Niño and elevated US yields as key risks keeping Indian interest rates high in the near term.
Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs
Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.
Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
CLSA says Nifty has given a new signal on the charts; check potential returns and top midcap 'buys'
Laurence Balanco of CLSA has shared five midcap ideas: BSE, MCX, Apollo Tubes, Dixon Technologies and Aurobindo Pharma.
Tata Trusts to take up crucial issues at meeting in May
Meeting may discuss keeping Tata Sons private, and an extension for its chairman N. Chandrasekaran. It may also include a performance review of new-age businesses and an exit strategy for the Shapoorji Pallonji Group.